Crossmark

Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial

Crossref DOI link: https://doi.org/10.1186/s40164-023-00409-y

Published Online: 2023-05-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Suo, Xiaohui

Zheng, Fang

Wang, Dongmei

Zhao, Liyun

Liu, Jie

Li, Ling

Zhang, Zhihua

Zhang, Congcong

Li, Yinling

Yang, Sisi

Zhao, Xuemei

Shi, Rui

Wu, Yan

Jiao, Zongjiu

Song, Jiaojie

Zhang, Ling

Lu, Xinxiao

Yuan, Linyu

Gao, Sifeng

Zhang, Jilei

Zhao, Xingli

Bai, Guanchen

Liu, Kaiqi

Mi, Yingchang
License Information

Text and Data Mining valid from 2023-05-12

Version of Record valid from 2023-05-12
More Information

Article History

Received: 19 March 2023

Accepted: 3 May 2023

First Online: 12 May 2023

Declarations

:

: The study protocol was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Health Human Research Ethics Committee of Handan Central Hospital, Handan, Hebei, China. Written informed consent was obtained from the patients or patients’ parents/legal guardians.

: Written informed consent was acquired from the patients or their parents/lawful guardians before participating.

: All authors have read and approved the manuscript for publication.

: The authors have no competing interests to declare.

Document is current

Any future updates will be listed below